These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 15255086

  • 21. Evaluation of efficacy of heartworm preventive products at the FDA.
    Hampshire VA.
    Vet Parasitol; 2005 Oct 24; 133(2-3):191-5. PubMed ID: 16099105
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
    Schick A, Miller KL, Lanthier M, Dal Pan G, Nardinelli C.
    Drug Saf; 2017 Jun 24; 40(6):497-503. PubMed ID: 28342075
    [Abstract] [Full Text] [Related]

  • 23. FDA drug prescribing warnings: is the black box half empty or half full?
    Wagner AK, Chan KA, Dashevsky I, Raebel MA, Andrade SE, Lafata JE, Davis RL, Gurwitz JH, Soumerai SB, Platt R.
    Pharmacoepidemiol Drug Saf; 2006 Jun 24; 15(6):369-86. PubMed ID: 16294363
    [Abstract] [Full Text] [Related]

  • 24. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.
    Anthony M, Romero K, Malone DC, Hines LE, Higgins L, Woosley RL.
    Clin Pharmacol Ther; 2009 Oct 24; 86(4):425-9. PubMed ID: 19587643
    [Abstract] [Full Text] [Related]

  • 25. Prescription drug products; revocation of patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1982 Sep 07; 47(173):39147-55. PubMed ID: 10258154
    [Abstract] [Full Text] [Related]

  • 26. Boxed warnings and other FDA communication tools.
    Marks NS, Weiss K.
    Am Fam Physician; 2010 Feb 01; 81(3):259. PubMed ID: 20112882
    [No Abstract] [Full Text] [Related]

  • 27. Bringing greater transparency to "black box" warnings.
    Buckley NA, Rossi S.
    Clin Toxicol (Phila); 2011 Jul 01; 49(6):448-51. PubMed ID: 21824055
    [Abstract] [Full Text] [Related]

  • 28. Unapproved uses of approved drugs: The physician, the package insert, and the FDA.
    Pediatrics; 1978 Aug 01; 62(2):262-4. PubMed ID: 693165
    [No Abstract] [Full Text] [Related]

  • 29. Amendment of regulations regarding certain label statements on prescription drugs. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2002 Feb 01; 67(22):4904-7. PubMed ID: 11829025
    [Abstract] [Full Text] [Related]

  • 30. Drug safety labeling for doctors.
    Hecht A.
    FDA Consum; 1979 Oct 01; 13(8):12-3. PubMed ID: 10309108
    [Abstract] [Full Text] [Related]

  • 31. Food and Drug Administration approval process for ophthalmic drugs in the US.
    Lloyd R, Harris J, Wadhwa S, Chambers W.
    Curr Opin Ophthalmol; 2008 May 01; 19(3):190-4. PubMed ID: 18408492
    [Abstract] [Full Text] [Related]

  • 32. [Improvement of package insert CYP information for prescription drugs marketed in Japan].
    Hirata-Koizumi M, Saito M, Urano T, Miyake S, Hasegawa R.
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005 May 01; (123):12-8. PubMed ID: 16541745
    [Abstract] [Full Text] [Related]

  • 33. How should FDA regulate prescription drug promotion on the Internet?
    Opderbeck DW.
    Food Drug Law J; 1998 May 01; 53(1):47-61. PubMed ID: 11795336
    [Abstract] [Full Text] [Related]

  • 34. Drug labeling; orally ingested over-the-counter drug products containing calcium, magnesium, and potassium. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2004 Mar 24; 69(57):13725-35. PubMed ID: 15040351
    [Abstract] [Full Text] [Related]

  • 35. FDA proposes new rules for off-label use of prescription drugs. Food and Drug Administration.
    Baker R.
    BETA; 1998 Jul 24; ():8-9. PubMed ID: 11365570
    [Abstract] [Full Text] [Related]

  • 36. From off-label prescribing towards a new FDA.
    Tabarrok A.
    Med Hypotheses; 2009 Jan 24; 72(1):11-3. PubMed ID: 18835103
    [Abstract] [Full Text] [Related]

  • 37. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2008 Aug 22; 73(164):49603-10. PubMed ID: 18958946
    [Abstract] [Full Text] [Related]

  • 38. Rx with a dose of info.
    Miller RW.
    FDA Consum; 1980 Nov 22; 14(9):22-3. PubMed ID: 10309292
    [Abstract] [Full Text] [Related]

  • 39. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.
    Wysowski DK, Nourjah P, Swartz L.
    Arch Intern Med; 2007 Jul 09; 167(13):1414-9. PubMed ID: 17620536
    [Abstract] [Full Text] [Related]

  • 40. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
    Cowden AL, Katz KA.
    Br J Dermatol; 2006 May 09; 154(5):950-8. PubMed ID: 16634900
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.